AU5465498A - Analysis and separation of platelet-derived growth factor proteins - Google Patents

Analysis and separation of platelet-derived growth factor proteins

Info

Publication number
AU5465498A
AU5465498A AU54654/98A AU5465498A AU5465498A AU 5465498 A AU5465498 A AU 5465498A AU 54654/98 A AU54654/98 A AU 54654/98A AU 5465498 A AU5465498 A AU 5465498A AU 5465498 A AU5465498 A AU 5465498A
Authority
AU
Australia
Prior art keywords
isoforms
proteins
pdgf
platelet
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU54654/98A
Other languages
English (en)
Inventor
Michael Kunitani
Hugh Parker
Patricia Tekamp-Olson
An D. Tran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU5465498A publication Critical patent/AU5465498A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
AU54654/98A 1996-12-13 1997-12-12 Analysis and separation of platelet-derived growth factor proteins Abandoned AU5465498A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3272096P 1996-12-13 1996-12-13
US60032720 1996-12-13
PCT/US1997/022815 WO1998025963A1 (en) 1996-12-13 1997-12-12 Analysis and separation of platelet-derived growth factor proteins

Publications (1)

Publication Number Publication Date
AU5465498A true AU5465498A (en) 1998-07-03

Family

ID=21866458

Family Applications (2)

Application Number Title Priority Date Filing Date
AU54654/98A Abandoned AU5465498A (en) 1996-12-13 1997-12-12 Analysis and separation of platelet-derived growth factor proteins
AU57945/98A Abandoned AU5794598A (en) 1996-12-13 1997-12-12 Method for expression of heterologous proteins in yeast

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU57945/98A Abandoned AU5794598A (en) 1996-12-13 1997-12-12 Method for expression of heterologous proteins in yeast

Country Status (9)

Country Link
US (10) US6017731A (https=)
EP (4) EP1365028B1 (https=)
JP (4) JP4341859B2 (https=)
AT (3) ATE398139T1 (https=)
AU (2) AU5465498A (https=)
DE (3) DE69725881T2 (https=)
ES (1) ES2306462T3 (https=)
PT (1) PT948538E (https=)
WO (2) WO1998025963A1 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486491T2 (de) 1983-04-25 2003-01-16 Chiron Corp., Emeryville Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren
US5811381A (en) * 1996-10-10 1998-09-22 Mark A. Emalfarb Cellulase compositions and methods of use
US7883872B2 (en) * 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
DE69725881T2 (de) * 1996-12-13 2004-09-09 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Verfahren zur expression von heterologen proteinen in hefe
ES2237159T3 (es) * 1998-10-06 2005-07-16 Mark Aaron Emalfarb Sistema de transformacion en el campo de los hongos micoticos filamentosos en chrysosporium.
US20040146918A1 (en) * 2000-02-18 2004-07-29 Weiner Michael L. Hybrid nucleic acid assembly
US7166712B2 (en) * 2000-07-12 2007-01-23 Philadelphia, Health And Education Corporation Mammalian MDM2 binding proteins and uses thereof
EP1596813A4 (en) * 2003-01-31 2008-02-20 Five Prime Therapeutics Inc POLYPEPTIDES EXPRESSED IN THE LUNG
CN103484486B (zh) 2003-07-02 2018-04-24 维莱尼姆公司 葡聚糖酶，编码它们的核酸以及制备和使用它们的方法
DE10342794A1 (de) * 2003-09-16 2005-04-21 Basf Ag Sekretion von Proteinen aus Hefen
EP1689348B1 (en) 2003-12-05 2013-05-15 Children's Hospital Medical Center Oligosaccharide compositions and use thereof in the treatment of infection
EP2327724A3 (en) * 2004-02-02 2011-07-27 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
JP2008507280A (ja) * 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
US7473678B2 (en) * 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US8114841B2 (en) * 2004-10-14 2012-02-14 Biomimetic Therapeutics, Inc. Maxillofacial bone augmentation using rhPDGF-BB and a biocompatible matrix
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
CN102732588B (zh) 2004-12-22 2015-01-07 Ambrx公司 氨酰基-tRNA合成酶的组合物及其用途
EP1828224B1 (en) 2004-12-22 2016-04-06 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
GB2438760A (en) * 2004-12-22 2007-12-05 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
JP2008525473A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 修飾されたヒト成長ホルモン
WO2006133089A2 (en) * 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
JP2009501522A (ja) * 2005-07-12 2009-01-22 コドン デバイシズ インコーポレイテッド 生体触媒工学のための組成物及び方法
MX2008002149A (es) 2005-08-18 2008-04-22 Ambrx Inc Composiciones de arnt y sus usos.
FR2891149B1 (fr) 2005-09-26 2007-11-30 Biodex Sarl Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes.
CN104710503B (zh) * 2005-11-08 2023-04-25 Ambrx 公司 用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
EP1951890A4 (en) 2005-11-16 2009-06-24 Ambrx Inc PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS
DK1968635T3 (en) * 2005-12-14 2014-12-15 Ambrx Inc Compositions and Methods of, and uses of non-natural amino acids and polypeptides
ES2427993T3 (es) 2006-02-09 2013-11-05 Biomimetic Therapeutics, Llc Composiciones y métodos para el tratamiento de hueso
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
CA2656278C (en) 2006-06-30 2016-02-09 Biomimetic Therapeutics, Inc. Compositions and methods for treating rotator cuff injuries
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
MX2009002460A (es) 2006-09-08 2009-03-20 Ambrx Inc Arnt supresor hibrido para celulas de vertebrados.
EP2064333B1 (en) 2006-09-08 2014-02-26 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
US8106008B2 (en) 2006-11-03 2012-01-31 Biomimetic Therapeutics, Inc. Compositions and methods for arthrodetic procedures
US9862956B2 (en) 2006-12-10 2018-01-09 Danisco Us Inc. Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
EP2505651A3 (en) 2006-12-10 2013-01-09 Dyadic International, Inc. Isolated fungus with reduced protease activity
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
MX2009011870A (es) 2007-05-02 2009-11-12 Ambrx Inc Polipeptidos de interferon beta modificados y usos de los mismos.
CA2736661A1 (en) * 2007-09-07 2009-03-12 Dyadic International, Inc. Novel fungal enzymes
MX2010005317A (es) * 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
EP2259807B1 (en) 2008-02-07 2013-04-24 Biomimetic Therapeutics, Inc. Compositions for distraction osteogenesis
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
PT2318029T (pt) 2008-07-23 2018-01-10 Ambrx Inc Polipéptidos de g-csf bovino modificados e suas utilizações
KR20110067035A (ko) 2008-09-09 2011-06-20 바이오미메틱 세라퓨틱스, 인크. 건 및 인대 손상의 치료를 위한 혈소판-유래 성장 인자 조성물 및 방법
MX2011003272A (es) 2008-09-26 2011-04-28 Ambrx Inc Polipeptidos de eritropoyetina animal modificados y sus usos.
PE20110480A1 (es) 2008-09-26 2011-07-01 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales
US8183346B2 (en) * 2008-12-05 2012-05-22 Eli Lilly And Company Anti-ferroportin 1 monoclonal antibodies and uses thereof
JP2013515081A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
CN102811622A (zh) 2010-02-22 2012-12-05 生物模拟治疗公司 用于治疗腱病的血小板衍生生长因子组合物和方法
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
MA34521B1 (fr) 2010-08-17 2013-09-02 Ambrx Inc Polypeptides de relaxine modifiés et leurs utilisations
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CN105085652B (zh) * 2014-05-16 2021-06-22 中国人民解放军军事医学科学院生物工程研究所 血小板衍生生长因子b突变体、其制备方法及用途
MX2017004520A (es) * 2014-10-14 2018-03-15 Lynch Samuel Composiciones para tratar heridas.
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
CN106496302B (zh) * 2015-09-08 2021-12-10 三生国健药业（上海）股份有限公司 一种用离子交换层析纯化蛋白质的方法
CN108239648B (zh) * 2016-12-26 2023-04-07 丰益(上海)生物技术研发中心有限公司 高效表达米黑根毛霉脂肪酶的方法
CN110637027B (zh) 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
CN110590930B (zh) * 2018-06-13 2023-03-31 四川好医生攀西药业有限责任公司 美洲大蠊生长因子pdgf在制备损伤修复药物中的应用
CN113015782A (zh) * 2018-11-19 2021-06-22 巴斯夫欧洲公司 用于酵母的前导序列

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2359180A (en) * 1942-08-11 1944-09-26 Gen Motors Corp Dynamic balancer
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US5010003A (en) * 1983-04-25 1991-04-23 Genentech, Inc. Use of yeast homologous signals to secrete heterologous proteins
US4889919A (en) 1986-08-13 1989-12-26 Zymogenetics, Inc. Biologically active PDGF derived A-chain homodimers
US4769328A (en) 1984-10-12 1988-09-06 Zymogenetics Inc. Expression of biologically active PDGF analogs in yeast
US5187263A (en) 1984-10-12 1993-02-16 Zymogenetics, Inc. Expression of biologically active PDGE analogs in eucaryotic cells
EP0487116B1 (en) * 1984-10-12 1999-12-29 ZymoGenetics, Inc. Biologically active PDGF analogs in eucaryotic cells
US4766073A (en) * 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4801542A (en) 1984-10-12 1989-01-31 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US5516896A (en) * 1985-02-25 1996-05-14 Zymogenetics, Inc. Biologically active B-chain homodimers
US5045633A (en) * 1985-02-25 1991-09-03 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
AU5912586A (en) * 1985-06-20 1986-12-24 Salk Institute Biotechnology/Industrial Associates, Inc., The Alpha-factor leader peptide-facilitated secretion from transformed s cerevisiae
EP0259632B1 (en) * 1986-08-13 1995-12-13 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US5019559A (en) 1986-11-14 1991-05-28 President And Fellows Of Harvard College Wound healing using PDGF and IGF-II
IE60517B1 (en) 1986-11-14 1994-07-27 Inst Molecular Biology Inc Wound healing and bone regeneration
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5219759A (en) * 1987-04-22 1993-06-15 Chiron Corporation Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors
CA1340772C (en) * 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US5094941A (en) * 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
DE3900770A1 (de) * 1989-01-12 1990-07-26 Juergen Prof Dr Hoppe Verfahren zur herstellung von pdgf-a und pdgf-aa
US5968778A (en) * 1989-01-12 1999-10-19 Jurgen Hoppe PDGF-AB, preparation process and pharmaceuticals containing them
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
JPH0768139B2 (ja) 1990-04-10 1995-07-26 インスティチュート・オブ・モレキュラー・バイオロジー・インコーポレーテッド 創傷の治癒
US5962219A (en) * 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
DE69102651T2 (de) * 1990-07-23 1994-10-06 Zymogenetics, Inc., Seattle, Wash. Proteaseresistenter pdgf und dessen verwendungen.
JP3257675B2 (ja) * 1990-10-12 2002-02-18 マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー．ファウ． 修飾リボザイム
DK300090D0 (da) * 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
DE4216134A1 (de) * 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
WO1993008825A1 (en) 1991-11-04 1993-05-13 Zymogenetics, Inc. Pdgf gel formulation
EP0681482B1 (en) * 1993-01-22 2005-12-07 University Research Corporation Localization of therapeutic agents
PT695169E (pt) 1993-04-22 2003-04-30 Skyepharma Inc Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
DK82893D0 (da) * 1993-07-08 1993-07-08 Novo Nordisk As Peptid
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
PT729351E (pt) 1993-11-16 2000-12-29 Skyepharma Inc Vesiculas com libertacao controlada de activos
US5902880A (en) * 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5627053A (en) * 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
CA2187626C (en) * 1994-04-13 2009-11-03 Michael G. Kaplitt Aav-mediated delivery of dna to cells of the nervous system
US5639642A (en) * 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
ZA954983B (en) * 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
US6146886A (en) * 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5716824A (en) * 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
ZA9610456B (en) * 1995-12-20 1997-06-20 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
DE69725881T2 (de) * 1996-12-13 2004-09-09 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Verfahren zur expression von heterologen proteinen in hefe
US6248878B1 (en) * 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6001311A (en) * 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
US6395713B1 (en) * 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules

Also Published As

Publication number Publication date
US20030036511A1 (en) 2003-02-20
ATE426030T1 (de) 2009-04-15
ATE398139T1 (de) 2008-07-15
US7166446B2 (en) 2007-01-23
US6897043B2 (en) 2005-05-24
US6083910A (en) 2000-07-04
ES2306462T3 (es) 2008-11-01
US20050124042A1 (en) 2005-06-09
EP1935901A1 (en) 2008-06-25
WO1998026080A1 (en) 1998-06-18
US20060252695A1 (en) 2006-11-09
EP0948538A1 (en) 1999-10-13
ATE253120T1 (de) 2003-11-15
US20020055169A1 (en) 2002-05-09
DE69725881T2 (de) 2004-09-09
US7084262B2 (en) 2006-08-01
DE69725881D1 (de) 2003-12-11
US6312923B1 (en) 2001-11-06
DE69739319D1 (de) 2009-04-30
US20030077831A1 (en) 2003-04-24
JP2008031173A (ja) 2008-02-14
DE69738768D1 (de) 2008-07-24
EP0946736B1 (en) 2003-10-29
JP2008119008A (ja) 2008-05-29
AU5794598A (en) 1998-07-03
JP4341859B2 (ja) 2009-10-14
JP2001506497A (ja) 2001-05-22
EP1365028B1 (en) 2009-03-18
EP1365028A1 (en) 2003-11-26
US6706496B2 (en) 2004-03-16
US6083723A (en) 2000-07-04
EP0946736A1 (en) 1999-10-06
PT948538E (pt) 2008-08-05
US6017731A (en) 2000-01-25
EP0948538B1 (en) 2008-06-11
US6448382B1 (en) 2002-09-10
WO1998025963A1 (en) 1998-06-18
JP4275741B2 (ja) 2009-06-10
JP2001518073A (ja) 2001-10-09

Similar Documents

Publication Publication Date Title
AU5465498A (en) Analysis and separation of platelet-derived growth factor proteins
ATE187462T1 (de) Reinigung von alpha-l-proteinaseinhibitor mittels neuen chromatographischen trennungsbedingungen
IL128736A0 (en) Methods using cre-lox for production of recombinant adeno-associated viruses
EP1612272A3 (en) Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis
AU1957097A (en) Protein separations by capillary electrophoresis using amino acid-containing buffers
ATE73856T1 (de) Reinigung, herstellung und verwendung von tumor- nekrosisfaktoren.
AU3471697A (en) An improved method for the capillary electrophoresis of nucleic acids, proteins and low molecular charged compounds
AU4113385A (en) Bone protein purification process
DK0699687T3 (da) Fremgangsmåde til oprensning af rekombinant humant serumalbumin
JP2005520550A (ja) 所望エリスロポエチングリコアイソフォームプロフィールの製造方法
AU5672186A (en) Method for protein stabilization
DE3787090D1 (de) Methode fuer chromatographische trennung.
NO863902D0 (no) Fremgangsmaate ved opprensing av proteiner.
AU5481686A (en) Foldable framework for bed, stretcher or bridge
DK0789767T3 (da) Fremgangsmåde til fremstilling af oprensede papilomavirusproteiner
DK99690A (da) Fremgangsmaade til rensning af protein
AU7817387A (en) Purification of recombinant tumor necrosis factor
CA2143510A1 (en) Method for the Isolation and Purification of Vitamin K-Dependent Proteins
CA2077888A1 (en) Method for purifying factor viii and preparations obtained
EP0749312A4 (en) DIROFILARIA IMMITIS - Gp29 - PROTEINS, NUCLEIC ACID MOLECULES AND THEIR USE
EP0239311A3 (en) Mutual separation of proteins
FI971100L (fi) Menetelmä yhdistelmä-DNA-proteiinien, plasmidien ja modifioitujen solujen tuottamiseksi
CA2274241A1 (en) A process for purifying apolipoprotein a or apolipoprotein e from human plasma
DK0906255T3 (da) Fremgangsmåde til fremstilling af enantiomert ren azetidin-2-carboxylsyre
ES2193349T3 (es) Metodo para la produccion de rdspa alfa1.